Loading people...
Jill Carroll is a Managing Partner at SR One Capital Management based in the Greater Philadelphia Area. Before joining the venture firm in 2012, she worked in corporate development at Dynavax Technologies and life sciences strategy consulting at Clearview Healthcare Partners. She holds a Master of Science in Biochemistry from Johns Hopkins University and a Bachelor of Science in Chemistry from Duke University. At SR One, she co-manages the firm's $600 million Fund II and directs investments across a growing portfolio that includes Arcellx, Odyssey, and Avalyn. Her investment track record features board directorships at several biotechnology companies, including CRISPR Therapeutics and Mineralys Therapeutics, which completed a $192 million initial public offering in 2023. Carroll currently focuses her venture capital strategy on early-stage therapeutic companies developing innovative clinical medicines for significant unmet patient needs.
Jill Carroll is a distinguished Principal at SR One, a premier independent venture capital firm with a rich history of investing in transformative life sciences companies. At SR One, Jill plays a pivotal role in identifying, evaluating, and nurturing promising early stage and growth stage ventures across the biotechnology and broader healthcare landscape. Her work is instrumental in SR One's mission to back innovative science and technology that addresses significant unmet medical needs.
Jill's investment focus areas are broad within life sciences, encompassing novel therapeutics, cutting edge diagnostics, innovative medical devices, and disruptive digital health solutions. She is particularly interested in companies leveraging breakthrough scientific discoveries to develop first in class or best in class products. Her approach involves deep scientific diligence combined with a keen understanding of market dynamics and commercial potential, ensuring that SR One's investments are strategically positioned for long term success and impact.
While specific details of Jill Carroll's career background are not publicly detailed, professionals in her role at SR One typically possess a robust foundation in science, medicine, or a related technical field, often complemented by significant experience in venture capital, corporate development, or pharmaceutical R&D. This blend of scientific acumen and business expertise allows her to effectively assess complex scientific platforms and translate them into viable investment opportunities. Her background likely includes a strong track record of identifying emerging trends and technologies that have the potential to reshape healthcare.
Though individual notable investments are often attributed to the firm as a whole, Jill Carroll is actively involved in SR One's portfolio management, contributing to the strategic growth and development of its invested companies. She works closely with founders and management teams, providing guidance and leveraging SR One's extensive network to accelerate company progress. Her contributions help these innovative companies navigate the challenging path from concept to commercialization, ultimately bringing new solutions to patients worldwide. Jill Carroll's dedication to advancing life sciences innovation makes her a key figure in the venture capital ecosystem.
Jill Carroll is a Principal at SR One, an independent venture capital firm focused on investing in innovative life sciences companies. She plays a key role in identifying and supporting promising ventures in biotechnology and healthcare.
Jill Carroll invests in a wide range of life sciences sectors, including novel therapeutics, cutting edge diagnostics, innovative medical devices, and disruptive digital health solutions. She focuses on companies with breakthrough scientific discoveries.
Jill Carroll works as a Principal at SR One, a leading independent venture capital firm dedicated to investing in and supporting transformative life sciences companies.
